English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 3 February 2023, 10:01 HKT/SGT

Source: Ocumension Therapeutics
Ocumension Therapeutics Announces The Completion Of The Phase I Clinical Trial Of Its Class I New Drug For The Treatment Of Dry Eye -- OT-202

HONG KONG, Feb 3, 2023 - (ACN Newswire) - Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a China-based ophthalmic pharmaceutical platform company, announces that the phase I clinical trial of OT-202 (tyrosine kinase inhibitor), a class I new drug developed by the Company for the treatment of dry eye, has been completed successfully.

The phase I clinical trial of OT-202 was designed as a randomized, double-masked, placebo-controlled clinical trial on the safety, tolerance and pharmacokinetic properties of its single/multiple administration on healthy adult subjects in China.

Mr. Ye LIU, the Executive Director and CEO of Ocumension Therapeutics said, "OT-202 (tyrosine kinase inhibitor) is a class I innovative drug developed by the Company for the treatment of moderate to severe dry eye. A total of 30 subjects were enrolled for the phase I clinical trial in China. OT-202 demonstrated good safety and tolerability profile in healthy adult subjects in the phase I clinical trial. Currently, we are in the process of advancing the study for the phase II clinical trial."

The mechanism of action of OT-202 is that the dual-targeted inhibitor of spleen tyrosine kinase (Syk) and vascular endothelial growth factor receptor achieves a synergistic effect in the treatment of dry eye diseases and inhibits the inflammatory response.

More information about Ocumension Therapeutics: https://www.ocumension.com/

Topic: Press release summary
Source: Ocumension Therapeutics

Sectors: BioTech, Healthcare & Pharm
From the Asia Corporate News Network

Copyright © 2023 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


Ocumension Therapeutics Related News
Mar 30, 2023 22:31 HKT/SGT
Mar 30, 2023 22:30 HKT/SGT
Mar 30, 2023 22:29 HKT/SGT
Ocumension Therapeutics Announces 2022 Annual Results
Mar 13, 2023 18:32 HKT/SGT
Mar 13, 2023 18:31 HKT/SGT
More news >>
Copyright © 2023 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575